Perspectives on Signal Intelligence, behavior-based coaching, and building judgment through practice — from the team behind ReflectivAI.
MIT's NANDA initiative found that 95% of enterprise generative AI pilots fail to deliver measurable financial return, while only about 5% successfully scale to deliver rapid revenue impact.
Field rep access to HCPs has fallen to pre-pandemic levels: only 45% are accessible to biopharmas, down from 60% eighteen months earlier, and half of those restrict engagement to digital channels.
Pharma's agentic AI pilots keep working. Scaling them keeps stalling. The real bottleneck isn't data quality — it's who decides which HCP-facing moments belong to a machine and which don't.
Two forces, shrinking physician access and AI automation, are turning the live clinical conversation into the highest-leverage and hardest-to-scale asset in life sciences commercial. A behavioral framework for measuring and scaling judgment.
There is a coaching perception gap: 90% of leaders say they coach monthly, but 38% of reps say they rarely or never receive it.
AI sales coaches are being trusted to judge how reps perform — but they invent objections that were never raised, stay confident when they're wrong, and penalize the wrong things. Here is the credibility standard that separates real coaching signal from algorithmic noise.
Signal Intelligence is the ability to notice, interpret, and respond to the observable signals in a high-stakes conversation. Here is what it means, why it is behavior-based, and how commercial teams put it into practice.
Numeric scorecards feel objective but quietly break coaching. Here is the case for behavior-based feedback — specific, in the moment, and always human-led — and how it changes what managers and reps do differently.
The first time a rep handles a hard HCP objection should not be in front of the HCP. Here is why deliberate rehearsal against adaptive AI personas builds judgment and fluency that role-play scripts never could.